HEMISPHERIAN AS
Developing novel small molecule drugs targeting TET2 for aggressive cancers.
Overview
- 5
- Employees
- 269K NOK
- Revenue
- 2020
- Founded
Key Decision Makers
Roger Stupp
Chair of the Clinical Advisory Board
Michael Lim
Member of the Clinical Advisory Board
Monika Hegi
Member of the Clinical Advisory Board
Einar O. Vik-Mo
Member of the Clinical Advisory Board
+2 more contacts in Funnelfeedr
Description
Hemispherian is an innovative preclinical pharmaceutical company dedicated to redefining targeted cancer therapeutics. The core focus is developing a novel class of small molecule drugs that specifically target the TET2 enzyme. These compounds are designed as targeted therapies for particularly aggr...